Hydroxymethylglutaryl-CoA Reductase Inhibitors
"Hydroxymethylglutaryl-CoA Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
| Descriptor ID |
D019161
|
| MeSH Number(s) |
D27.505.519.186.071.202.370 D27.505.519.389.370 D27.505.954.557.500.202.370
|
| Concept/Terms |
Hydroxymethylglutaryl-CoA Reductase Inhibitors- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hydroxymethylglutaryl CoA Reductase Inhibitors
- Inhibitors, Hydroxymethylglutaryl-CoA Reductase
- Reductase Inhibitors, Hydroxymethylglutaryl-CoA
- Inhibitors, HMG-CoA Reductase
- Inhibitors, HMG CoA Reductase
- Reductase Inhibitors, HMG-CoA
- HMG-CoA Reductase Inhibitors
- HMG CoA Reductase Inhibitors
- Statins, HMG-CoA
- HMG-CoA Statins
- Statins, HMG CoA
- Inhibitors, Hydroxymethylglutaryl-CoA
- Hydroxymethylglutaryl-CoA Inhibitors
- Inhibitors, Hydroxymethylglutaryl CoA
- Statins
- Inhibitors, Hydroxymethylglutaryl-Coenzyme A
- Hydroxymethylglutaryl-Coenzyme A Inhibitors
- Inhibitors, Hydroxymethylglutaryl Coenzyme A
|
Below are MeSH descriptors whose meaning is more general than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
This graph shows the total number of publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in this website by year, and whether "Hydroxymethylglutaryl-CoA Reductase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 2 | 4 | 6 |
| 2006 | 4 | 0 | 4 |
| 2007 | 3 | 1 | 4 |
| 2008 | 4 | 2 | 6 |
| 2009 | 4 | 0 | 4 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 2 | 4 |
| 2013 | 3 | 2 | 5 |
| 2014 | 5 | 1 | 6 |
| 2015 | 1 | 1 | 2 |
| 2016 | 4 | 1 | 5 |
| 2017 | 3 | 0 | 3 |
| 2018 | 2 | 1 | 3 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 2 | 1 | 3 |
| 2022 | 2 | 0 | 2 |
| 2023 | 4 | 0 | 4 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Profiles.
-
Hadgu A, Yan F, Effoe V, Mayberry R. Statin use and its association with all-cause mortality and incident diabetes/prediabetes in African Americans: Findings from the jackson heart study. J Natl Med Assoc. 2024 Dec; 116(6):682-693.
-
Lee SY, Paul ME, Coleman AL, Kitayama K, Yu F, Pan D, Tseng VL. Associations between Statin Use and Glaucoma in the All of Us Research Program. Ophthalmol Glaucoma. 2024 Nov-Dec; 7(6):563-571.
-
Alrajeh K, AlAzzeh O, Roman Y. The frequency of major ABCG2, SLCO1B1 and CYP2C9 variants in Asian, Native Hawaiian and Pacific Islander women subgroups: implications for personalized statins dosing. Pharmacogenomics. 2023 05; 24(7):381-398.
-
Steg PG, Szarek M, Valgimigli M, Islam S, Zeiher AM, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Goodman SG, Gotcheva N, Harrington RA, Jukema JW, Kim HS, Kim SH, Morais J, Pordy R, Scemama M, White HD, Schwartz GG. Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome. Can J Cardiol. 2023 10; 39(10):1315-1324.
-
AlAzzeh O, Roman YM. The frequency of rs2231142 in ABCG2 among Native Hawaiian and Pacific Islander subgroups: implications for personalized rosuvastatin dosing. Pharmacogenomics. 2023 02; 24(3):173-182.
-
Alrajeh K, Roman YM. The frequency of rs2231142 in ABCG2?among Asian subgroups: implications for personalized rosuvastatin dosing. Pharmacogenomics. 2023 01; 24(1):15-26.
-
Patel KK, Sehgal VS, Kashfi K. Molecular targets of statins and their potential side effects: Not all the glitter is gold. Eur J Pharmacol. 2022 May 05; 922:174906.
-
Watanabe LM, Seale LA. Challenging Aspects to Precise Health Strategies in Native Hawaiian and Other Pacific Islanders Using Statins. Front Public Health. 2022; 10:799731.
-
Patel KK, Kashfi K. Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs. Biochem Pharmacol. 2022 02; 196:114654.
-
Watanabe LM, Navarro AM, Seale LA. Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil. Nutrients. 2021 Jun 12; 13(6).